Giphar in the news

Hoche Avocats advised Giphar on its majority stake acquisition in PharmaPlatinum.

Giphar has acquired a majority stake in PharmaPlatinum, marking its first external growth initiative to expand its market share and integrate logistics.

Giphar has acquired a majority stake in PharmaPlatinum as its first external growth move to expand its independent pharmacy network and logistics platform.

Celltrion is integrating its acquisition of Giphar to expand its direct sales of biosimilars and other healthcare products into French pharmacies, with plans to replicate this strategy across Europe.

Giphar has launched its 2026 GipharLab program by selecting nine startups to pilot new health and wellness products across its pharmacy network.

Seven French pharmacy chains, led by Giphar, exceeded one billion euros in revenue, demonstrating significant growth and market strength.

Celltrion has acquired the French pharmacy network Giphar to boost its biosimilar distribution and expand into the over-the-counter drug market.

Giphar strengthens its 'Copilote' program to offer comprehensive support for pharmacy installations, guiding pharmacists from project conception through to the initial months of operation, including financial and operational assistance.

Pharmacie Giphar du Bocage in Dijon provides a teledermatology service for rapid skin issue diagnosis and treatment recommendations within 24-48 hours.

Giphar pharmacies have conducted extensive blood pressure screenings and prevention interviews, moving towards paid health services and increased patient self-monitoring.

The Métropole Européenne de Lille is transforming the former Giphar site into a modern, flexible biotech and health innovation hub within the nearly saturated Eurasanté park.

Strategic procurement transformation focuses on aligning purchasing with marketing and circular economy principles to ensure business resilience and environmental impact.

A 6,000 m² site formerly used by Giphar Technologies in Loos will be redeveloped into new offices and labs starting in 2027.

Over 1,200 Giphar member pharmacists have adopted mandatory branding, boosting Giphar's recognition as France's leading pharmacy brand amid ongoing legal challenges.

Giphar is running a campaign to raise awareness and detect malnutrition risks among elderly patients through pharmacist-led questionnaires.

MEL is redeveloping the former Giphar site in Loos with a new 6,000 m² hybrid building to support Eurasanté's expanding health sector and innovation.

MTRL's president defends their preventive health assessment against medical order's criticism, clarifying it is not a medical consultation but a preventive measure.

MEL will redevelop the Giphar site at Eurasanté in Loos with a 6,000 m² hybrid building to support health sector companies while preserving public land ownership.

Seven leading pharmacy networks, including Giphar, have been ranked among France's top retail banners for 2024.

French pharmacy groupings have shifted from purchasing alliances to service-oriented networks, undergoing consolidation and preparing for future economic and operational challenges.